Evidence-based recommendations on gammaCore for cluster headache.
NICE has developed tools, in association with relevant stakeholders, to help organisations put this guidance into practice.
Next review: 2022
NICE medical technologies guidance addresses specific technologies notified to NICE by sponsors. The ‘case for adoption’ is based on the claimed advantages of introducing the specific technology compared with current management of the condition. This case is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.
This guidance replaces NICE medtech innovation briefing on gammaCore for cluster headache (MIB162).